NRx Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and addressing unmet medical needs in neurology and infectious diseases. The company offers a pipeline of product candidates including NRX-101 for bipolar depression and akathisia; NRX-100 for catatonia and bipolar depression; NRX-102 for bipolar depression with mixed features and agitation; and ZYESAMI (aviptadil) for critical care indications such as COVID-19-related acute lung injury and sarcoidosis. These therapies target severe psychiatric conditions, central nervous system diseases, and respiratory distress, with clinical trials emphasizing rapid symptom relief and reduced reliance on sedatives or antipsychotics. Founded in 2011 and headquartered in Radnor, Pennsylvania, NRx operates primarily in the United States with global clinical trial collaborations. Recent developments include positive Phase 3 trial data for NRX-101 in bipolar depression with suicidality, submission of New Drug Applications to the FDA, and a strategic licensing agreement for NRX-102 in the European market. In 2025, the company announced expansions in its pipeline through partnerships for combination therapies and secured additional funding via equity offerings to support ongoing trials and regulatory milestones.
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
My Top 3 Biotech Stocks for May 2026
NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty
NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update